-
September 23, 2009ABCSG-24 trial results presented in Berlin:
Further optimizing breast cancer therapyThe neoadjuvant therapy protocol ABCSG-24 was activated in Austria in mid-2004. The clinical objective of this study was to investigate to what extent rates of complete pathologic remission could be improved (i.e., breast cancer cells eliminated completely, as seen in patients’ dissected material).
Today in Berlin, Prof. Günther Steger, MD, presented impressive trial results from ABCSG-24.
read more ....
October 5, 2009
ABCSG-24 in the media - Coverage listA total of 10 pieces of coverage of the ABCSG-24 study have appeared on online and print media
up to 1 October 2009.
read more ....
-
February 12, 2009
ABCSG treatment makes history:
ABCSG-12 trial results published in the New England Journal of Medicine
ABCSG Trial 12 demonstrated that bisphosphonate treatment added to standard therapy reduces the risk of recurrence by 36% in premenopausal women with hormone receptor-sensitive breast cancer as compared to patients receiving conventional antihormonal treatment. The renowned New England Journal of Medicine published this result in its current issue – an honor rarely bestowed on researchers in Austria.
read more ....
- September 23, 2008
Breast cancer: Risk of relapse can be reduced by 36 percent
Recently, the chances of healing breast cancer patients have drastically improved: Following succesful surgery, a novel treatment approach has the potential to reduce the risk of a recurrent cancer by 36 percent. In this respect, the ABCSG has issued a folder with the most up-to-date details. The folder can be ordered from www.abcsg.at and has been deposited at more than 100 of the Group's centers.
- August 25, 2008
Results of ABCSG Trial Published in Lancet Oncology
Lancet Oncology yesterday published the online version of a paper dealing with bone mineral density data from ABSCG Trial 12. The ABCSG is grateful to and congratulates all co-authors of this publication. The print version is to be released in September.
Download Publication
-
August 27, 2008 International Study
Soon To Come in Austria ABCSG-30, BETH
The ABCSG is the first institution in Europe to launch the new Bevacizumab and Trastuzumab Adjuvant Therapy (BETH) trial, ABCSG-30. A total of 16 centers will be taking part in this study protocol. The trial investigates the integration of the anti-vascular endothelial growth factor antibody bevacizumab into a trastuzumab treatment plan for early-stage HER2-positive breast cancer. Pre-study visits are currently well underway.
-
June 4, 2008 PRIME Oncology Expert Interviews from Chicago, Illinois
PRIME Oncology invites you to view the interview with Dr. Lee Lokey and
Dr. Michael Gnant, discussing data presented on Sunday, June 1, 2008.
This interview will focus on the following:
Abstract No: LBA4 Adjuvant ovarian suppression combined with tamoxifen
or anastrozole, alone or in combination with zoledronic acid, in premenopausal
women with hormone-responsive, stage I and II breast cancer: First efficacy
results from ABCSG-12.
Link: Video
- October 19, 2009 media coverage generated by the ABCSG-24 studyIt has appeared on the following global website:
The Cancer Foundation
24 September 2009
www.thecancerfoundationfortheworld.org
- October 11, 2009 ABCSG takes part in the IBIS-II-study5.000 women have already been recruited to IBIS II worldwide, even more are needed
www.ibis-trials.org
Pressrelease
-
June 23, 2009
In the media Cancer World, Juli/August 2009
Cover Story
Michael Gnant:
Pushing the boundaries
Download article
Link: Cancer World
read more ....
- October 31, 2008
100 Patients in ABCSG-25 (Panther)
After a virtual upswing in recruitment over the past 2 weeks, we are pleased to announce:
OVER 100 PATIENTS HAVE NOW BEEN RANDOMIZED INTO PANTHER !
We are grateful to all patients participating in ABCSG-25 and to all Principal Investigators for their substantial contributions. Let’s continue!
- September 18, 2008
ABCSG in the media
L'Espresso, 28 Aug 2008
L'Espresso is one of the most important Italian news magazines
with a circulation of about 400.000 copies a week.
Terapia in agguato
Download
- September 15, 2008 Another successful publication
for the ABCSG Lancet Oncology releases follow-up data from the ABCSG-12 bone mineral density subprotocol
This journal applies demanding measures on authors to exclusively publish the most significant and up-to-date international research results. The ABCSG has again been successful in attracting scientific attention with the bone mineral density subprotocol of ABCSG Trial 12.
Feel free to download the
Lancet Oncology paper from here
- August 28, 2008 The Lancet Oncology published the substudy of the ABCSG-12 Concomitant zoledronic acid prevents bone loss in women with breast cancer during treatment with adjuvant endocrine therapy, and improves bone-mineral density after treatment, according to findings from a substudy of the Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12), published early Online and in the September edition of The Lancet Oncology.
Download Press release
- June 23, 2008
Information for ABCSG12 Investigators:
The Webcast of the Zoledronic Acid Investigator Meeting that was held during
the annual meeting of the American Society of Clinical Oncology (ASCO) on 1 June
2008 in Chicago, Illinois, is now available for you to access
Detailed Information in the Members-Area
- June 10, 2008
Daily Clinical Updates
from the Annual Oncology Meeting in Chicago
Zoledronic Acid Demonstrates Significant Disease-Free Survival Advantages
in Premenopausal Women with Endocrine-Responsive Breast Cancer Compared
With Endocrine Therapy Alone
Link: www.primeoncology.org
